Spotlight on Affective disorders in neurologic disease

In this article, Dr. Sergio Starkstein of the University of Western Australia and Dr. Jaime Pahissa of the Instituto Universitario CEMIC review the frequency, diagnostic strategies, clinical correlates, mechanism, differential diagnoses, and management of affective disorders in frequent acute and chronic neurologic disorders, such as stroke, traumatic brain injury, dementia, Parkinson disease, Huntington disease, multiple sclerosis, and epilepsy. Studies using sophisticated neuroimaging techniques have provided important clues regarding the mechanism of depression and disinhibition in neurologic conditions. Randomized clinical trials have been reported for depression in stroke, Parkinson disease, and Alzheimer disease as well as for the prevention of depression after stroke.

To view the complete article, click here and log in.

Spotlight on Alzheimer disease

Alzheimer disease is the prototypical and, by far, most common dementia. In this clinical summary, Dr. David S Geldmacher, Director of the Division of Memory Disorders and Behavioral Neurology at the University of Alabama at Birmingham, presents an overview of the disease including clinical manifestations, pathophysiology, etiology, and diagnostic workup. Also included is information on recent results from clinical trials of exercise and treatments for neuropsychiatric symptoms.

To view the complete clinical summary, click here.

MedLink Neurology authors are always at work to bring you broad and up-to-date coverage of neurology topics. We are pleased to highlight clinical summaries that have been recently added or updated and to introduce the authors who write these authoritative articles. We hope you enjoy these overviews and appreciate the contributions of our more than 450 authors who keep MedLink Neurology the premier information resource for neurologists.

Spotlight on Neurodegenerative disorders: treatment with neurotrophic factors

Neurotrophic factors are polypeptides that regulate the proliferation, survival, migration, and differentiation of cells in the nervous system. Neurotrophic factor therapy is based on the evidence that these factors stimulate the survival of degenerating neurons. In this clinical summary, Dr. K K Jain of Basel, Switzerland reviews the role of neurotrophic factors for therapy of neurodegenerative disorders. Delivery to the CNS is a problem because the large neurotrophic molecules cannot cross the blood-brain barrier, and methods to overcome this are described. Several clinical trials have failed, but others are in progress. Gene therapy with stereotactic implantation into the putamen of the gene for neurturin, a member of the same family as glial cell line-derived neurotrophic factor, is in phase II clinical trials for Parkinson disease. A similar gene therapy approach for Alzheimer disease using nerve growth factor has shown neuroprotective effect in phase I clinical trials. Vascular endothelial growth factor, delivered by an intracerebroventricular pump, is in phase II/III clinical trials for amyotrophic lateral sclerosis.

To view the complete clinical summary, click here.

MedLink Neurology authors are always at work to bring you broad and up-to-date coverage of neurology topics. We are pleased to highlight clinical summaries that have been recently added or updated and to introduce the authors who write these authoritative articles. We hope you enjoy these overviews and appreciate the contributions of our more than 450 authors who keep MedLink Neurology the premier information resource for neurologists.